NASDAQ Framework: Repligen Corporation
Global life sciences company, bioprocessing technologies 1.
1: Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America. View Source
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. The company serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Repligen's focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Headquartered in Waltham, Massachusetts, the company has the majority of its manufacturing sites in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands, and Sweden 234.
2: About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn. View Source3: About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn. View Source4: Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn. View Source
5: Karen A. Dawes, current Board Chair at Repligen, stated, “Over the past two years, the Repligen Board has developed a leadership succession plan to provide for the Company’s ongoing success. Elevating Tony Hunt to Executive Chair and promoting Olivier Loeillot to CEO ensures that we will continue to have a clear strategic vision and achieve our long-term goals. Tony has been an outstanding CEO and we thank him for his leadership and continued commitment to the Company. Olivier, given his exceptional experience and the positive impact he has made since joining Repligen, is an ideal successor to Tony. The Board is confident that he will build on our strong foundation and successfully lead Repligen through the next phase of growth.” View Source6: Tony J. Hunt, current CEO at Repligen, said, “It has been my privilege to lead Repligen for over nine years and execute on the vision we set to bring disruptive, high value bioprocessing technologies to market. Having known and respected Olivier for many years – and now having worked directly with him over the past months – I share the Board’s confidence that Olivier is an excellent choice for the CEO role and for the future of Repligen. As Executive Chair, I look forward to working with Olivier and focusing on corporate strategy, new product and business opportunities.” View Source7: Olivier Loeillot, President and Chief Commercial Officer at Repligen, said, “I am delighted and honored to take on the leadership role of President and CEO. Repligen is highly regarded in the bioprocessing industry and has achieved remarkable success under Tony’s leadership. Since joining this results-focused team, I have been very impressed with the company’s culture of innovation, commitment to its employees and customers, and its drive for excellence. I look forward to working with Tony and the Board to lead this high-performing organization to an even more successful future.” View Source8: Mr. Hunt has served as Chief Executive Officer and a member of the Company’s Board of Directors since May 2015, successfully leading the Company to innovation leadership in bioprocessing. Under his direction, the Company has enjoyed consistent above-industry growth through disciplined acquisitions (M&A), internal product development (R&D), commercial execution and operational excellence. During Mr. Hunt’s tenure as CEO, Repligen’s revenue grew from approximately $63 million in 2014 to $639 million in 2023, representing an average annual growth rate of over 30% over the nine-year period. View Source
LOW RISK
Repligen Corporation is profitable and has demonstrated consistent above-industry growth under the leadership of Tony J. Hunt, with revenue increasing from approximately $63 million in 2014 to $639 million in 2023 9. The company continues to innovate and expand its product offerings, maintaining a strong market presence in the bioprocessing industry 101112. Additionally, the recent CEO transition plan ensures continued strategic vision and leadership stability 131415.
Repligen Corporation is profitable and has demonstrated consistent above-industry growth under the leadership of Tony J. Hunt, with revenue increasing from approximately $63 million in 2014 to $639 million in 2023 9. The company continues to innovate and expand its product offerings, maintaining a strong market presence in the bioprocessing industry 101112. Additionally, the recent CEO transition plan ensures continued strategic vision and leadership stability 131415.
9: Mr. Hunt has served as Chief Executive Officer and a member of the Company’s Board of Directors since May 2015, successfully leading the Company to innovation leadership in bioprocessing. Under his direction, the Company has enjoyed consistent above-industry growth through disciplined acquisitions (M&A), internal product development (R&D), commercial execution and operational excellence. During Mr. Hunt’s tenure as CEO, Repligen’s revenue grew from approximately $63 million in 2014 to $639 million in 2023, representing an average annual growth rate of over 30% over the nine-year period. View Source10: Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America. View Source11: About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn. View Source12: Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. View Source13: Karen A. Dawes, current Board Chair at Repligen, stated, “Over the past two years, the Repligen Board has developed a leadership succession plan to provide for the Company’s ongoing success. Elevating Tony Hunt to Executive Chair and promoting Olivier Loeillot to CEO ensures that we will continue to have a clear strategic vision and achieve our long-term goals. Tony has been an outstanding CEO and we thank him for his leadership and continued commitment to the Company. Olivier, given his exceptional experience and the positive impact he has made since joining Repligen, is an ideal successor to Tony. The Board is confident that he will build on our strong foundation and successfully lead Repligen through the next phase of growth.” View Source14: Tony J. Hunt, current CEO at Repligen, said, “It has been my privilege to lead Repligen for over nine years and execute on the vision we set to bring disruptive, high value bioprocessing technologies to market. Having known and respected Olivier for many years – and now having worked directly with him over the past months – I share the Board’s confidence that Olivier is an excellent choice for the CEO role and for the future of Repligen. As Executive Chair, I look forward to working with Olivier and focusing on corporate strategy, new product and business opportunities.” View Source15: Olivier Loeillot, President and Chief Commercial Officer at Repligen, said, “I am delighted and honored to take on the leadership role of President and CEO. Repligen is highly regarded in the bioprocessing industry and has achieved remarkable success under Tony’s leadership. Since joining this results-focused team, I have been very impressed with the company’s culture of innovation, commitment to its employees and customers, and its drive for excellence. I look forward to working with Tony and the Board to lead this high-performing organization to an even more successful future.” View Source
NO
There is no indication that Repligen Corporation is launching any new product offerings at this time 16.
There is no indication that Repligen Corporation is launching any new product offerings at this time 16.
16: All Releases Display: All Releases Search Press Releases All Years20242023202220212020201920182017201620152014201320122011201020092008 Subscribe for Email Alerts Subscribe to RSS feed List View Grid View Date Headline Format 7/16/20247:30 AM ETPress ReleaseRepligen to Report Second Quarter 2024 Financial Results7/16/2024 SummaryWebcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ET WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (... Continue Reading6/13/20247:00 AM ETPress ReleaseRepligen Announces CEO Transition Plan6/13/2024 SummaryTony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Office... Continue Reading6/3/20248:00 AM ETPress ReleaseEcolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing6/3/2024 SummaryEcolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioproce... Continue Reading5/22/20247:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming June Investor Conferences5/22/2024 SummaryWALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/7/20247:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming May Investor Conferences5/7/2024 SummaryWALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/1/20247:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2024 Financial Results5/1/2024 SummaryReports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% y... Continue Reading4/17/20247:30 AM ETPress ReleaseRepligen to Report First Quarter 2024 Financial Results4/17/2024 SummaryWebcast and Conference Call to Be Held Wednesday, May 1, 2024, at 8:30 a.m. ET WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) - Repligen Corporation ... Continue Reading3/19/20247:30 AM ETPress ReleaseRepligen Appoints Maggie A. Pax to Board of Directors3/19/2024 SummaryWALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life... Continue Reading2/21/20247:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Full Year 2023 Financial Results2/21/2024 SummaryReports fourth quarter revenue of $156 million and full year revenue of $639 million Continued strength in orders with fourth quarter book-to-bill rat... Continue Reading2/7/20247:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2023 Financial Results2/7/2024 SummaryWebcast and Conference Call to Be Held Wednesday, February 21, 2024, at 8:30 a.m. ET WALTHAM, Mass., Feb. 07, 2024 (GLOBE NEWSWIRE) - Repligen Corpora... Continue Reading12/19/20237:30 AM ETPress ReleaseRepligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference12/19/2023 SummaryWALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading12/7/20237:30 AM ETPress ReleaseRepligen Announces Private Convertible Transaction of $600 Million Principal Amount of 1.00% Convertible Senior Notes Due 2028 Through Exchange and New Subscription Agreements12/7/2023 SummaryWALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that on December 6, 2023, it entered into private... Continue Reading11/14/20232:01 PM ETPress ReleaseUPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report11/14/2023 SummaryWALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/14/20237:30 AM ETPress ReleaseRepligen Announces Publication of the Company’s 2022 Sustainability Report11/14/2023 SummaryWALTHAM, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/7/20237:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming Investor Conferences11/7/2023 SummaryWALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/2/20237:30 AM ETPress ReleaseRepligen Launches TangenX® SC as First-to-Market Holder-Free Self-Contained TFF Device11/2/2023 Summary- Targeting ADC and Cell & Gene Therapy Customers - WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life scienc... Continue Reading10/31/20237:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance10/31/2023 SummaryReports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million Orders strengthened with total book-to-bill rati... Continue Reading10/17/20237:30 AM ETPress ReleaseRepligen to Report Third Quarter 2023 Financial Results10/17/2023 SummaryWebcast and Conference Call to Be Held Tuesday, October 31, 2023, at 8:30 a.m. ET WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) - Repligen Corporatio... Continue Reading10/2/20237:30 AM ETPress ReleaseRepligen Appoints Olivier Loeillot as President and Chief Commercial Officer10/2/2023 SummaryWALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading9/26/20237:30 AM ETPress ReleaseRepligen Announces Agreement to Acquire Fluid Management Innovator Metenova9/26/2023 SummaryProposed acquisition adds market leading magnetic mixing technology for upstream and downstream bioprocess applications Expands Repligen’s Fluid Manag... Continue Reading9/12/20237:30 AM ETPress ReleaseRepligen Appoints Jason K. Garland as Chief Financial Officer9/12/2023 SummaryWALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading9/1/20237:30 AM ETPress ReleaseRepligen Corporation to Present at Wells Fargo Healthcare Conference9/1/2023 SummaryWALTHAM, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading8/17/20238:00 AM ETPress ReleaseSartorius and Repligen Corporation Launch Integrated System with Biostat STR® and XCell® ATF for Upstream Process Intensification8/17/2023 SummaryBioreactor and cell retention technology integration features a single direct control interface to simplify intensified seed train implementation Cust... Continue Reading8/2/20237:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance8/2/2023 Summary– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full y... Continue Reading7/19/20237:30 AM ETPress ReleaseRepligen to Report Second Quarter 2023 Financial Results7/19/2023 SummaryWebcast and Conference Call to Be Held Wednesday, August 2, 2023, at 8:30 a.m. ET WALTHAM, Mass., July 19, 2023 (GLOBE NEWSWIRE) - Repligen Corporatio... Continue Reading5/31/20237:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming Investor Conferences5/31/2023 SummaryWALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/2/20237:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance5/2/2023 SummaryReports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross m... Continue Reading4/18/20237:30 AM ETPress ReleaseRepligen to Report First Quarter 2023 Financial Results4/18/2023 SummaryWebcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (N... Continue Reading3/14/20237:30 AM ETPress ReleaseRepligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum3/14/2023 SummaryWALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading2/22/20237:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Full Year 2022 Financial Results2/22/2023 SummaryFourth quarter revenue of $186.8 million represents year-over-year organic growth of 4% and 5% growth at constant currency Full year revenue of... Continue Reading2/9/20237:30 AM ETPress ReleaseRepligen Appoints Martin D. Madaus to Board of Directors2/9/2023 SummaryWALTHAM, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life ... Continue Reading2/8/20237:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2022 Financial Results2/8/2023 SummaryWebcast and Conference Call to Be Held Wednesday, February 22, 2023 at 8:30 a.m. EST WALTHAM, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) - Repligen Corpora... Continue Reading1/3/20237:30 AM ETPress ReleaseRepligen Corporation to Present at 41st Annual J.P. Morgan Healthcare Conference1/3/2023 SummaryWALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/8/20227:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming Investor Conferences11/8/2022 SummaryWALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/1/20227:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance11/1/2022 SummaryReports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Continue Reading11/1/20227:00 AM ETPress ReleaseRepligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands11/1/2022 SummaryWALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreemen... Continue Reading10/12/20227:30 AM ETPress ReleaseRepligen to Report Third Quarter 2022 Financial Results10/12/2022 SummaryWebcast and Conference Call to Be Held Tuesday, November 1, 2022 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) - Repligen Corporatio... Continue Reading9/19/20224:01 PM ETPress ReleaseRepligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement9/19/2022 SummarySigns 15-year Strategic Collaboration and Exclusive License Agreement WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:R... Continue Reading8/24/20227:30 AM ETPress ReleaseRepligen To Host Investor Day 20228/24/2022 SummaryWALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, ... Continue Reading8/2/20227:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance8/2/2022 SummaryRecord revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year) Strong ... Continue Reading7/19/20227:30 AM ETPress ReleaseRepligen to Report Second Quarter 2022 Financial Results7/19/2022 SummaryWebcast and Conference Call to Be Held Tuesday, August 2, 2022 at 8:30 a.m. EDT WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) - Repligen Corporation ... Continue Reading5/26/20224:30 PM ETPress ReleaseRepligen Appoints Dr. Konstantin Konstantinov to Board of Directors5/26/2022 SummaryWALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konsta... Continue Reading5/25/20227:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming Investor Conferences5/25/2022 SummaryWALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading4/27/20227:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance4/27/2022 Summary—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth o... Continue Reading4/13/20227:30 AM ETPress ReleaseRepligen to Report First Quarter 2022 Financial Results4/13/2022 SummaryWebcast and Conference Call to Be Held Wednesday, April 27, 2022 at 8:30 a.m. EDT WALTHAM, Mass., April 13, 2022 (GLOBE NEWSWIRE) - Repligen Corporati... Continue Reading3/18/20227:30 AM ETPress ReleaseRepligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum3/18/2022 SummaryWALTHAM, Mass., March 18, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading2/17/20227:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Full Year 2021 Financial Results2/17/2022 Summary— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72% — Record revenue of $670.5 million for the year, and year-... Continue Reading2/15/20227:30 AM ETPress ReleaseRepligen Launches AAV Affinity Resins for Gene Therapy Purification2/15/2022 SummaryAVIPure® affinity resins address the market need for high performance and caustic stability WALTHAM, Mass., Feb. 15, 2022 (GLOBE NEWSWIRE) - Repligen ... Continue Reading2/11/20227:30 AM ETPress ReleaseRepligen Corporation to Present at 11th Annual SVB Leerink Healthcare Conference2/11/2022 SummaryWALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading2/3/20229:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2021 Financial Results2/3/2022 SummaryWebcast and Conference Call to Be Held Thursday, February 17, 2022 at 8:30 a.m. EST WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) - Repligen Corporat... Continue Reading12/30/20217:30 AM ETPress ReleaseRepligen Corporation to Present at 40th Annual J.P. Morgan Healthcare Conference12/30/2021 SummaryWALTHAM, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/12/20217:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming Investor Conferences11/12/2021 SummaryWALTHAM, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/5/20217:30 AM ETPress ReleaseRepligen Releases Inaugural Sustainability Report11/5/2021 SummarySets Baseline and Provides SASB, GRI Core and SDG Disclosures WALTHAM, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) tod... Continue Reading10/28/20217:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance10/28/2021 SummaryReports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% Raises revenue guidance ... Continue Reading10/14/20217:30 AM ETPress ReleaseRepligen to Report Third Quarter 2021 Financial Results10/14/2021 SummaryWebcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) - Repligen Corporati... Continue Reading9/16/20217:40 AM ETPress ReleaseRepligen Announces Agreement to Acquire Avitide Inc.9/16/2021 SummaryProposed acquisition strengthens Repligen’s Proteins business Adds a market leader in affinity ligand discovery and development and complements establ... Continue Reading9/9/20217:30 AM ETPress ReleaseRepligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies9/9/2021 SummaryWALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading7/27/20217:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance7/27/2021 SummaryReported revenue was $163.0 million for the quarter, representing year-over-year growth of 86% and organic growth of 69% Revenue guidance raise... Continue Reading7/13/20217:30 AM ETPress ReleaseRepligen to Report Second Quarter 2021 Financial Results7/13/2021 SummaryWebcast and Conference Call to Be Held Tuesday, July 27, 2021 at 8:30 a.m. EDT WALTHAM, Mass., July 13, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (... Continue Reading6/22/20216:30 AM ETPress ReleaseRepligen Corporation Announces Agreement to Acquire Polymem S.A.6/22/2021 SummaryWALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading5/25/20217:30 AM ETPress ReleaseRepligen Corporation to Present at Upcoming Investor Conferences5/25/2021 SummaryWALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/4/20217:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance5/4/2021 SummaryReported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69% Growth driven by combi... Continue Reading4/20/20217:30 AM ETPress ReleaseRepligen to Report First Quarter 2021 Financial Results4/20/2021 SummaryWebcast and Conference Call to Be Held Tuesday, May 4, 2021 at 8:30 a.m. EDT WALTHAM, Mass., April 20, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (N... Continue Reading3/17/20217:30 AM ETPress ReleaseRepligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum3/17/2021 SummaryWALTHAM, Mass., March 17, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading3/3/20217:30 AM ETPress ReleaseRepligen Corporation to Present at Barclays Global Healthcare Conference3/3/2021 SummaryWALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading2/24/20217:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Full Year 2020 Financial Results2/24/2021 SummaryReports quarterly revenue of $108.6 million, representing 56% year-over-year growth, and annual revenue of $366.3 million represents 36% year-over-yea... Continue Reading2/22/20217:30 AM ETPress ReleaseRepligen Corporation to Present at 10th Annual SVB Leerink Healthcare Conference2/22/2021 SummaryWALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading2/11/20213:00 PM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2020 Financial Results2/11/2021 SummaryWebcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) - Rep... Continue Reading2/8/20217:36 AM ETPress ReleaseRepligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 Vaccines2/8/2021 SummaryWALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bio... Continue Reading1/4/20211:00 PM ETPress ReleaseRepligen Corporation to Present at 39th Annual J.P. Morgan Healthcare Conference1/4/2021 SummaryWALTHAM, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading12/10/20204:18 PM ETPress ReleaseRepligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters’ Option12/10/2020 SummaryWALTHAM, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the closing of its previously announced underwrit... Continue Reading12/7/20209:40 PM ETPress ReleaseRepligen Corporation Prices Public Offering of Shares of Common Stock12/7/2020 SummaryWALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of... Continue Reading12/7/20207:21 AM ETPress ReleaseRepligen Corporation Announces Proposed Public Offering of Shares of Common Stock12/7/2020 SummaryWALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offe... Continue Reading11/5/20207:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance11/5/2020 SummaryReports record quarterly revenue of $94.1 million with strong margin expansion Overall revenue grew 35% year-over-year, with organic growth of ... Continue Reading10/27/20204:15 PM ETPress ReleaseRepligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic Solutions10/27/2020 SummaryProposed A RTeSYN a cquisition adds gold standard single - use downstream bioprocessing s ystems Advances Repligen’s S ystems strategy in Filtr... Continue Reading10/22/20207:30 AM ETPress ReleaseRepligen to Report Third Quarter 2020 Financial Results10/22/2020 Summary- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST - WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) - Replige... Continue Reading10/1/20206:30 AM ETPress ReleaseRepligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines10/1/2020 SummaryWALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bio... Continue Reading7/30/20207:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance7/30/2020 SummaryReports record quarterly revenue of $87.5 million Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance t... Continue Reading7/15/20207:30 AM ETPress ReleaseRepligen to Report Second Quarter 2020 Financial Results7/15/2020 SummaryWebcast and Conference Call to Be Held Thursday, July 30, 2020 at 8:30 a.m. EDT WALTHAM, Mass., July 15, 2020 (GLOBE NEWSWIRE) - Repligen Corporation ... Continue Reading6/29/20207:30 AM ETPress ReleaseRepligen Announces Agreement to Acquire Engineered Molding Technology6/29/2020 SummaryExpands Single-Use Portfolio with Expertise in Silicone Molding and Tubing WALTHAM, Mass., June 29, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASD... Continue Reading6/15/20207:30 AM ETPress ReleaseRepligen Appoints Carrie Eglinton Manner to Board of Directors6/15/2020 SummaryWALTHAM, Mass., June 15, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive C... Continue Reading5/6/20207:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance5/6/2020 SummaryReports record quarterly revenue of $76.1 million Overall revenue grew 25% year-over-year, with organic growth of 16% Strong order load through ... Continue Reading4/22/20207:30 AM ETPress ReleaseRepligen to Report First Quarter 2020 Financial Results4/22/2020 SummaryWALTHAM, Mass., April 22, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 20... Continue Reading2/27/20207:30 AM ETPress ReleaseRepligen Appoints Rohin Mhatre, Ph.D. to Board of Directors2/27/2020 SummaryWALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executiv... Continue Reading2/20/20207:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Full Year 2019 Financial Results2/20/2020 SummaryReports quarterly revenue of $69.5 million, representing 34% year-over-year growth, and annual revenue of $270.2 million represents 39% year-over-year... Continue Reading2/6/20207:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2019 Financial Results2/6/2020 SummaryWALTHAM, Mass., Feb. 06, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter an... Continue Reading1/7/20207:30 AM ETPress ReleaseRepligen to Present at the 38th Annual J.P. Morgan Healthcare Conference1/7/2020 SummaryWALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading10/31/20197:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance10/31/2019 SummaryReports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year Raises revenue guidance to $2... Continue Reading10/23/201910:29 AM ETPress ReleaseRepligen to Report Third Quarter 2019 Financial Results10/23/2019 SummaryWALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 201... Continue Reading8/1/20197:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance8/1/2019 SummaryReports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 ... Continue Reading7/23/20194:01 PM ETPress ReleaseRepligen to Report Second Quarter 2019 Financial Results7/23/2019 SummaryWALTHAM, Mass., July 23, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 20... Continue Reading7/19/20197:42 PM ETPress ReleaseRepligen Corporation Announces Closing of Public Offerings of $138.1 Million of Common Stock and $287.5 Million of 0.375% Convertible Senior Notes due 2024, Including Full Exercise of Underwriters’ Options7/19/2019 SummaryWALTHAM, Mass., July 19, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the closing of its pre... Continue Reading7/17/201912:14 AM ETPress ReleaseRepligen Corporation Announces Pricing of Public Offerings of $120 million of Common Stock and $250 million of 0.375% Convertible Senior Notes due 20247/17/2019 SummaryWALTHAM, Mass., July 17, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced the pricing of concurr... Continue Reading7/15/20194:02 PM ETPress ReleaseRepligen Corporation Announces Proposed Public Offerings of $100 million of Common Stock and $250 million of Convertible Senior Notes7/15/2019 SummaryWALTHAM, Mass., July 15, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) (“Repligen”) today announced that it has commenced ... Continue Reading6/4/201910:03 AM ETPress ReleaseRepligen to Present at Jefferies 2019 Healthcare Conference6/4/2019 SummaryWALTHAM, Mass., June 04, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading5/9/20197:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance5/9/2019 SummaryReports first quarter revenue of $60.6 million, representing 35% year-over-year growth and 37% organic growth Raises revenue guidance to $235-$241 mil... Continue Reading5/2/20192:20 PM ETPress ReleaseRepligen to Report First Quarter 2019 Financial Results5/2/2019 SummaryWALTHAM, Mass., May 02, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2019... Continue Reading4/30/20197:36 PM ETPress ReleaseRepligen Corporation Prices Public Offering of Shares of Common Stock4/30/2019 SummaryWALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering o... Continue Reading4/29/20194:19 PM ETPress ReleaseRepligen Corporation Announces Proposed Public Offering of Shares of Common Stock4/29/2019 SummaryWALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public off... Continue Reading4/26/20197:30 AM ETPress ReleaseRepligen Corporation Announces Agreement to Acquire Process Analytics Innovator C Technologies and Reports Preliminary First Quarter 2019 Financial Results4/26/2019 SummaryProposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing Adds a market le... Continue Reading2/21/20197:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Full Year 2018 Financial Results2/21/2019 SummaryRecord quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-y... Continue Reading2/15/20197:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2018 Financial Results2/15/2019 SummaryWALTHAM, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter an... Continue Reading1/3/20191:26 PM ETPress ReleaseRepligen to Present at 37th Annual J.P. Morgan Healthcare Conference1/3/2019 SummaryWALTHAM, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/1/20187:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2018 Financial Results11/1/2018 SummaryRecord quarterly revenue of $49.5 million represents 35% year-over-year growth Revenue guidance raised to $191-$194 million for full year 2018 WALTHAM... Continue Reading10/22/20187:30 AM ETPress ReleaseRepligen to Report Third Quarter 2018 Financial Results10/22/2018 Summary- Webcast and Conference Call to Be Held Thursday, November 1, 2018 at 8:30 a.m. EDT - WALTHAM, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) - Repligen Corpo... Continue Reading9/4/201811:05 AM ETPress ReleaseSartorius Stedim Biotech and Repligen Corporation Partner to Introduce Next-Generation Perfusion-Enabled Bioreactors9/4/2018 SummaryDevelopment collaboration integrates Sartorius Stedim Biotech’s BIOSTAT® STR bioreactors and Repligen’s XCell™ ATF cell rete... Continue Reading8/2/20187:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2018 Financial Results8/2/2018 SummaryRecord quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018 WALTHAM... Continue Reading7/19/201811:48 AM ETPress ReleaseRepligen to Report Second Quarter 2018 Financial Results7/19/2018 SummaryWALTHAM, Mass., July 19, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter of... Continue Reading6/28/20187:30 AM ETPress ReleaseRepligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand6/28/2018 SummaryWALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading6/27/20187:30 AM ETPress ReleaseRepligen Announces Agreement with Navigo Proteins for the Exclusive Co-Development of Next Generation Affinity Ligands6/27/2018 SummaryWALTHAM, Mass., June 27, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading5/30/20187:30 AM ETPress ReleaseRepligen to Present at the William Blair 2018 Growth Stock Conference5/30/2018 SummaryWALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and comm... Continue Reading5/23/20187:30 AM ETPress ReleaseRepligen to Present at Jefferies 2018 Global Healthcare Conference5/23/2018 SummaryWALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and comm... Continue Reading5/17/20187:30 AM ETPress ReleaseRepligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference5/17/2018 SummaryWALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading life sciences company focused on bioprocessing technolog... Continue Reading5/8/20187:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2018 Financial Results5/8/2018 SummaryRecord quarterly revenue of $44.8M represents 46% year-over-year growth Revenue guidance raised to $182-$188 million for full year 2018 WALTHAM, Mass.... Continue Reading4/30/201811:00 AM ETPress ReleaseRepligen to Report First Quarter 2018 Financial Results4/30/2018 SummaryWALTHAM, Mass., April 30, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter of... Continue Reading3/20/20187:30 AM ETPress ReleaseRepligen Announces Market Launch of OPUS® 80R, Reinforces Technology Leadership in Pre-Packed Chromatography3/20/2018 Summary- First and only available 80 cm diameter pre-packed column to address large-scale clinical and commercial-scale manufacturing of biological drugs - <... Continue Reading2/22/20187:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter 2017 Financial Results, Provides Guidance for 20182/22/2018 Summary- Revenue for 2017 increased by 35% to $141.2 million (36% at constant currency) - - GAAP EPS for 2017 more than doubled to $0.72, including a p... Continue Reading2/16/20187:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2017 Financial Results2/16/2018 SummaryWALTHAM, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and fu... Continue Reading12/29/20171:47 PM ETPress ReleaseRepligen To Present at 36th Annual J.P. Morgan Healthcare Conference12/29/2017 SummaryWALTHAM, Mass., Dec. 29, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading bioprocessing-focused company delivering technology inn... Continue Reading11/9/20177:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2017 Financial Results11/9/2017 SummaryRecord quarterly revenue of $36.6 million represents 48% year-over-year growth Year-to-date revenue of $99.6 million represents 26% year-over-ye... Continue Reading11/7/20177:30 AM ETPress ReleaseRepligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands11/7/2017 SummaryWaltham, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that is has extended a long-term supply agreement ... Continue Reading11/1/201711:14 AM ETPress ReleaseRepligen to Report Third Quarter 2017 Financial Results11/1/2017 SummaryWALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report third quarter of 2017... Continue Reading9/15/20177:30 AM ETPress ReleaseRepligen Announces Analyst Day and Webcast9/15/2017 SummaryWALTHAM, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will host an institutional inves... Continue Reading8/30/20173:20 PM ETPress ReleaseRepligen to Present at Baird’s 2017 Global Healthcare Conference8/30/2017 SummaryWALTHAM, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading8/3/20177:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2017 Financial Results8/3/2017 SummaryRecord quarterly revenue of $32.5 million First half 2017 revenue growth of 16% or 18% at constant currency Enters agreement to acquire Spectrum, Inc.... Continue Reading7/27/20177:00 AM ETPress ReleaseRepligen to Report Second Quarter 2017 Financial Results7/27/2017 SummaryWALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter of 201... Continue Reading6/27/20177:05 PM ETPress ReleaseRepligen Corporation Prices Public Offering of Shares of Common Stock6/27/2017 SummaryWALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced the pricing of an underwritten public offering of ... Continue Reading6/26/20175:12 PM ETPress ReleaseRepligen Corporation Announces Proposed Public Offering of Shares of Common Stock6/26/2017 SummaryWALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it has commenced an underwritten public offer... Continue Reading6/23/20177:00 AM ETPress ReleaseRepligen Corporation and Spectrum, Inc. to Join Forces6/23/2017 Summary- Adds to Repligen a leader in bioprocess filtration with expertise in hollow fiber technology - Strengthens flagship XCell™ ATF product ... Continue Reading5/31/20177:30 AM ETPress ReleaseRepligen to Present at Jefferies’ 2017 Global Annual Healthcare Conference5/31/2017 SummaryWALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/24/20177:30 AM ETPress ReleaseRepligen to Participate in 14th Annual Craig-Hallum Institutional Investor Conference5/24/2017 SummaryWALTHAM, Mass., May 24, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/9/20171:25 PM ETPress ReleaseRepligen to Present at Bank of America Merrill Lynch 2017 Healthcare Conference5/9/2017 SummaryWALTHAM, Mass., May 09, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading5/4/20177:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2017 Financial Results5/4/2017 SummaryRecord quarterly revenue of $30.6 million reflects 22% year-over-year growth or 24% at constant currency Company increases net income and EPS gu... Continue Reading4/21/20177:30 AM ETPress ReleaseRepligen to Report First Quarter 2017 Financial Results4/21/2017 SummaryWALTHAM, Mass., April 21, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter of 201... Continue Reading2/22/20177:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 20172/22/2017 SummaryFourth quarter 2016 revenue of $25.6 million reflects 19% growth Full year 2016 revenue of $104.5 reflects 25% growth Full year 2016 GAAP ... Continue Reading2/16/20175:02 PM ETPress ReleaseRepligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 20172/16/2017 SummaryWALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and fu... Continue Reading1/4/20177:30 AM ETPress ReleaseRepligen to Present at 35th Annual J.P. Morgan Healthcare Conference1/4/2017 SummaryWALTHAM, Mass., Jan. 04, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading12/15/20167:41 AM ETPress ReleaseUPDATE -- Repligen Acquires TangenX Technology Corporation12/15/2016 SummaryWALTHAM, Mass., Dec. 15, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading11/7/201611:27 AM ETPress ReleaseRepligen to Participate in Stephens Inc. Fall Investment Conference 201611/7/2016 SummaryWALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improv... Continue Reading11/3/20167:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2016 Financial Results11/3/2016 SummaryWALTHAM, Mass., Nov. 03, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading10/20/20167:30 AM ETPress ReleaseRepligen to Report Third Quarter 2016 Financial Results10/20/2016 SummaryWALTHAM, Mass., Oct. 20, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report third quarter 2016 fi... Continue Reading10/18/20167:30 AM ETPress ReleaseRepligen Hires Ralf Kuriyel as Senior Vice President of Research & Development10/18/2016 SummaryWALTHAM, Mass., Oct. 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading10/5/20168:00 AM ETPress ReleaseRepligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification10/5/2016 SummaryComplements Stainless Steel ATF Technology with Innovative Single-Use Format Improves Ease of Use for Biopharmaceutical Manufacturing Customers Offers... Continue Reading9/1/20167:30 AM ETPress ReleaseRepligen to Present at Baird Global Healthcare Conference 20169/1/2016 SummaryWALTHAM, Mass., Sept. 01, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to impro... Continue Reading8/4/20167:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2016 Financial Results8/4/2016 SummaryWALTHAM, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leade... Continue Reading7/27/20167:30 AM ETPress ReleaseRepligen to Report Second Quarter 2016 Financial Results7/27/2016 SummaryWALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter 2016 f... Continue Reading6/2/20167:30 AM ETPress ReleaseRepligen to Present at Jefferies 2016 Healthcare Conference6/2/2016 SummaryWALTHAM, Mass., June 02, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improv... Continue Reading5/26/20162:52 PM ETPress ReleaseRepligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference5/26/2016 SummaryWALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve... Continue Reading5/19/20168:41 AM ETPress ReleaseRepligen Announces Pricing of $100 Million of 2.125% Convertible Senior Notes due 20215/19/2016 SummaryWALTHAM, Mass., May 19, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) today announced the pricing of an und... Continue Reading5/18/20164:20 PM ETPress ReleaseRepligen Announces Proposed Public Offering of $100 Million of Convertible Senior Notes due 20215/18/2016 SummaryWALTHAM, Mass., May 18, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) (the “Company”) has commenced an offering of $100 mil... Continue Reading5/5/20167:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2016 Financial Results5/5/2016 SummaryWALTHAM, Mass., May 05, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leader... Continue Reading4/29/201611:24 AM ETPress ReleaseRepligen to Report First Quarter 2016 Financial Results4/29/2016 SummaryWALTHAM, Mass., April 29, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter 2016 f... Continue Reading4/4/20167:30 AM ETPress ReleaseRepligen Acquires Atoll GmbH4/4/2016 SummaryWALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading3/31/20168:46 AM ETPress ReleaseRepligen Forms Scientific Advisory Board3/31/2016 SummaryWALTHAM, Mass., March 31, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology lead... Continue Reading2/25/20167:30 AM ETEarnings ReleaseRepligen Reports Fourth Quarter and Year 2015 Financial Results2/25/2016 Summary- Constant currency revenue growth of 45% for the fourth quarter, 47% for the year - - Gross margin expansion of 420 basis points to 57.8% for t... Continue Reading2/24/20164:59 PM ETPress ReleaseRepligen Announces Extension of Long Term Supply Agreement for Protein A2/24/2016 SummaryWALTHAM, Mass., Feb. 24, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it has extended through 2019 a key long-term ... Continue Reading2/17/20167:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2015 Financial Results2/17/2016 SummaryWALTHAM, Mass., Feb. 17, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and fu... Continue Reading11/11/20157:30 AM ETPress ReleaseRepligen to Present at the Stifel 2015 Healthcare Conference11/11/2015 SummaryWALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced its upcoming presentation at the Stifel 2015 Healt... Continue Reading11/5/20157:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2015 Financial Results11/5/2015 Summary- Product Sales Increase 31% to $19.8 Million - - Conference Call and Webcast Today at 8:30 a.m. ET - WALTHAM, Mass., Nov. 05, 2015 (GLOBE NEWSWIRE) -... Continue Reading10/22/20156:20 PM ETPress ReleaseCORRECTION -- Repligen to Report Third Quarter 2015 Financial Results10/22/2015 SummaryWALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report third quarter 2015 financial r... Continue Reading10/22/20157:30 AM ETPress ReleaseRepligen to Report Third Quarter 2015 Financial Results10/22/2015 SummaryWALTHAM, Mass., Oct. 22, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report third quarter 2015 financial r... Continue Reading9/15/20157:30 AM ETPress ReleaseRepligen Appoints Glenn P. Muir to Board of Directors9/15/2015 SummaryWALTHAM, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that life sciences industry veteran Glenn P. Muir... Continue Reading8/6/20157:30 AM ETEarnings ReleaseRepligen Reports Second Quarter 2015 Financial Results8/6/2015 SummaryProduct Sales Increase 38% to a Record $21.5 Million Conference Call and Webcast Today at 8:30 a.m. ET WALTHAM, Mass., ... Continue Reading7/29/20157:30 AM ETPress ReleaseRepligen to Report Second Quarter 2015 Financial Results7/29/2015 SummaryWALTHAM, Mass., July 29, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN) today announced that it will report second quarter 2015 financial ... Continue Reading5/26/20151:00 PM ETPress ReleaseRepligen to Present at Jefferies 2015 Healthcare Conference5/26/2015 SummaryWALTHAM, Mass., May 26, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced its upcoming presentation at the Jefferies 2015 Hea... Continue Reading5/7/20157:30 AM ETEarnings ReleaseRepligen Reports First Quarter 2015 Financial Results5/7/2015 Summary- Product Sales Increase 45% to a Record $20.8 Million - - Conference Call and Webcast Today at 8:30 a.m. EDT - WALTHAM, Mass., May 7, 201... Continue Reading4/29/20157:30 AM ETPress ReleaseRepligen to Report First Quarter 2015 Financial Results4/29/2015 SummaryWALTHAM, Mass., April 29, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2015 financial ... Continue Reading3/13/20157:00 AM ETEarnings ReleaseRepligen Reports Financial Results for the Year 2014 and Issues 2015 Financial Guidance3/13/2015 Summary- Year 2014 Product Sales Increase 27% to a Record $60.4 Million - - Fourth Quarter Product Sales Increase 49% to $15.4 Million - - Conference Call an... Continue Reading3/9/20153:09 PM ETPress ReleaseRepligen to Report Year 2014 Financial Results and Provide 2015 Financial Guidance3/9/2015 SummaryWALTHAM, Mass., March 9, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and full year 2... Continue Reading2/10/20157:30 AM ETPress ReleaseRepligen Completes Expansion of U.S. Facility2/10/2015 SummaryWALTHAM, Mass., Feb. 10, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has completed an 11,000 square foot expans... Continue Reading2/4/20157:30 AM ETPress ReleaseRepligen to Present at 2015 Leerink Global Healthcare Conference2/4/2015 SummaryWALTHAM, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink G... Continue Reading1/21/20157:00 AM ETPress ReleaseRepligen Corporation Names Tony Hunt as Next Chief Executive Officer1/21/2015 SummaryWALTHAM, Mass., Jan. 21, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that its Board of Directors has appointed Tony J. ... Continue Reading1/8/20157:30 AM ETPress ReleaseRepligen Receives Milestone Payment From Pfizer1/8/2015 SummaryWALTHAM, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that on December 30, 2014, it received a $1 million... Continue Reading11/12/20147:30 AM ETPress ReleaseRepligen to Present at Stifel Healthcare Conference 201411/12/2014 SummaryWALTHAM, Mass., Nov. 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief... Continue Reading11/6/20147:30 AM ETEarnings ReleaseRepligen Reports Third Quarter 2014 Financial Results11/6/2014 SummaryProduct Revenue Increases 24% to $15.2 Million Product Gross Profit Increases 26% to $8.2 Million Conference Call and Webcast Today at 8:30 a.m. EST W... Continue Reading11/5/20141:17 PM ETPress ReleaseRepligen to Present at Stephens Inc. Fall Investment Conference11/5/2014 SummaryWALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief ... Continue Reading10/23/20147:30 AM ETPress ReleaseRepligen to Report Third Quarter 2014 Financial Results10/23/2014 SummaryWALTHAM, Mass., Oct. 23, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2014 financial r... Continue Reading10/10/201411:23 AM ETPress ReleaseRepligen to Host Investor & Analyst Event on October 1610/10/2014 Summary- Discussion of Biomanufacturing Trends and Technologies Will be Webcast - WALTHAM, Mass., Oct. 10, 2014 (GLOBE NEWSWIRE) -Repligen Corporation (Nasda... Continue Reading8/11/20147:00 AM ETEarnings ReleaseRepligen Reports Second Quarter 2014 Financial Results8/11/2014 SummaryProduct Revenue Increases 19.5% to a Record $15.6 Million Product Gross Profit Increases 15.1% to a Record $8.9 Million Conference Call and Webcast To... Continue Reading7/28/20147:30 AM ETPress ReleaseRepligen to Report Second Quarter 2014 Financial Results7/28/2014 SummaryWALTHAM, Mass., July 28, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2014 financial ... Continue Reading7/15/20147:30 AM ETPress ReleaseRepligen Hires Jon K. Snodgres as Chief Financial Officer7/15/2014 SummaryWALTHAM, Mass., July 15, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Jon K. Snodgres has been named its Chief Fina... Continue Reading6/12/20149:52 AM ETPress ReleaseRepligen Appoints Nicolas M. Barthelemy to Board of Directors6/12/2014 SummaryWALTHAM, Mass., June 12, 2014 (GLOBE NEWSWIRE) - Repligen Corporation today announced that it has elected life sciences and biopharmaceutical industry... Continue Reading6/3/20147:00 AM ETPress ReleaseRepligen Acquires Bioprocessing Business of Refine Technology6/3/2014 Summary- Expands Portfolio of Products to Improve Efficiencies in Biologic Drug Manufacturing - - Company Updates 2014 Financial Guidance - - Conference Call... Continue Reading5/28/20144:15 PM ETPress ReleaseRepligen to Present at Jefferies 2014 Global Healthcare Conference5/28/2014 SummaryWALTHAM, Mass., May 28, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief ... Continue Reading5/8/20147:00 AM ETEarnings ReleaseRepligen Reports First Quarter 2014 Financial Results5/8/2014 Summary- Product Revenue Increases 20% to a Record $14.3 Million - - Net Income Increases 83% to $4.3 Million - - Conference Call and Webcast Today at 8:30 a... Continue Reading5/6/20147:00 AM ETPress ReleaseRepligen Hires Former Life Technologies Executive Tony J. Hunt as Chief Operating Officer5/6/2014 SummaryWALTHAM, Mass., May 6, 2014 (GLOBE NEWSWIRE) - Repligen Corporation, a life sciences company focused on the manufacture and commercialization of biopr... Continue Reading4/25/20142:03 PM ETPress ReleaseRepligen to Report First Quarter 2014 Financial Results4/25/2014 SummaryWALTHAM, Mass., April 25, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report first quarter 2014 financial ... Continue Reading3/26/20147:30 AM ETPress ReleaseRepligen Launches OPUS(R) Ready-to-Use Chromatography Columns With Largest Capacity Available on the Market3/26/2014 SummaryWALTHAM, Mass., March 26, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN), a technology leader in pre-packed columns for the cost-effective... Continue Reading3/6/20147:30 AM ETEarnings ReleaseRepligen Reports Full Year and Fourth Quarter 2013 Financial Results3/6/2014 Summary- 2013 Product Revenue Growth of 13.5% - - Year-over-Year Net Income Up 13.7% to $16.1 Million - - Earnings Conference Call and Webcast Today at 9:00 ... Continue Reading2/25/20147:30 AM ETPress ReleaseRepligen to Report Fourth Quarter and Fiscal Year 2013 Financial Results2/25/2014 SummaryWALTHAM, Mass., Feb. 25, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report fourth quarter and fiscal year... Continue Reading1/21/20147:30 AM ETPress ReleaseRepligen Announces Asset Purchase Agreement With BioMarin for HDACi Portfolio1/21/2014 SummaryWALTHAM, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has entered into an asset purchase agreeme... Continue Reading11/26/20137:30 AM ETPress ReleaseRepligen to Present at the 25th Annual Piper Jaffray Healthcare Conference11/26/2013 SummaryWALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief... Continue Reading11/19/20132:00 PM ETPress ReleaseRepligen Appoints Biogen Idec Executive John G. Cox to Board of Directors11/19/2013 SummaryWALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) - Repligen Corporation today announced that it has elected to its Board of Directors John G. Cox, Execu... Continue Reading11/7/20137:30 AM ETPress ReleaseRepligen Reports Third Quarter 2013 Financial Results11/7/2013 Summary- Product Revenue Grows 10% for the Quarter - - Net Income Grows 226% to $5.9 Million - - Earnings Conference Call and Webcast Today at 9:00 a.m. EST ... Continue Reading11/6/20137:30 AM ETPress ReleaseRepligen to Present at the 2013 Stephens Fall Investment Conference11/6/2013 SummaryWALTHAM, Mass., Nov. 6, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief ... Continue Reading11/1/20137:30 AM ETPress ReleaseRepligen Completes Expansion of U.S. Manufacturing Facility11/1/2013 SummaryWALTHAM, Mass., Nov. 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced it has completed a 9,000 square foot expansion of i... Continue Reading10/24/20137:30 AM ETPress ReleaseRepligen to Report Third Quarter 2013 Financial Results10/24/2013 SummaryWALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report third quarter 2013 financial r... Continue Reading9/4/20138:00 AM ETPress ReleaseRepligen to Present at the Stifel Healthcare Conference 20139/4/2013 SummaryWALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief... Continue Reading9/4/20137:00 AM ETPress ReleaseRepligen Receives First Milestone Payment From Pfizer Under Licensing Agreement for Spinal Muscular Atrophy Program9/4/2013 SummaryWALTHAM, Mass., Sept. 4, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it has received a $1 million milestone paymen... Continue Reading8/1/20137:30 AM ETPress ReleaseRepligen Reports Second Quarter 2013 Financial Results8/1/2013 Summary- Product Revenue Grows 12% for the Quarter on Record Bioprocessing Sales - - Net Income Grows 189% to $4.5 Million - - Earnings Conference Call and W... Continue Reading7/18/20137:30 AM ETPress ReleaseRepligen to Report Second Quarter 2013 Financial Results7/18/2013 SummaryWALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report second quarter 2013 financial ... Continue Reading5/23/20131:39 PM ETPress ReleaseRepligen CEO to Present at Jefferies 2013 Global Healthcare Conference5/23/2013 SummaryWALTHAM, Mass., May 23, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief ... Continue Reading5/2/20137:30 AM ETPress ReleaseRepligen Reports First Quarter 2013 Financial Results5/2/2013 Summary- Total Revenue and Bioprocessing Revenue Grow 28% Over First Quarter 2012 - - Net Income Increases 91% to $2.3 million – - Earnings Conference... Continue Reading4/23/20135:35 PM ETPress ReleaseRepligen to Report First Quarter 2013 Financial Results4/23/2013 SummaryWALTHAM, Mass., April 23, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that it will report financial results for the fir... Continue Reading3/7/20137:30 AM ETPress ReleaseRepligen Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Financial Guidance for 20133/7/2013 Summary- Bioprocessing Revenue Increases to $42 Million, Total Revenue Reaches $63 Million in 2012 - - Year-over-Year Net Income Increases by $18 Million - W... Continue Reading3/1/20131:34 PM ETPress ReleaseRepligen to Report Fourth Quarter and Full Year 2012 Financial Results3/1/2013 SummaryWALTHAM, Mass., March 1, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) announced today that it will report financial results for the four... Continue Reading1/3/20137:30 AM ETPress ReleaseRepligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program1/3/2013 SummaryRepligen Corporation (NASDAQ:RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. to advance Rep... Continue Reading11/8/20127:30 AM ETPress ReleaseRepligen Reports Third Quarter 2012 Financial Results11/8/2012 SummaryRepligen Corporation (NASDAQ: RGEN) today reported financial results for its third quarter and year-to-date period ended September 30, 2012. The Compa... Continue Reading11/7/20127:30 AM ETPress ReleaseRepligen CEO to Present at Upcoming Investor Conferences11/7/2012 Summary- Stephens Fall Investment Conference & Piper Jaffray Healthcare Conference - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. He... Continue Reading10/26/20127:30 AM ETPress ReleaseRepligen To Report Third Quarter of 2012 Financial Results10/26/2012 Summary- Webcast and Conference Call to Be Held Thursday, November 8, 9:00 a.m. EST - Repligen Corporation (NASDAQ:RGEN) today announced that it will report ... Continue Reading9/21/20126:30 AM ETPress ReleaseRepligen Appoints Jonathan I. Lieber as CFO9/21/2012 Summary- Former CFO of Xcellerex, Inc. Joins Repligen Executive Management Team - Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jonat... Continue Reading8/29/20127:30 AM ETPress ReleaseRepligen to Present at Stifel Nicolaus Healthcare Conference 20128/29/2012 Summary- Thursday, September 6, 10:20 a.m. EDT - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Execut... Continue Reading8/2/20127:30 AM ETEarnings ReleaseRepligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results8/2/2012 SummaryRepligen Corporation (NASDAQ: RGEN) today reported financial results for its second quarter and year-to-date period ended June 30, 2012. In addition, ... Continue Reading7/24/20127:30 AM ETPress ReleaseRepligen To Report Second Quarter of 2012 Financial Results7/24/2012 Summary- Webcast and Conference Call to Be Held Thursday, August 2, 8:30 a.m. EDT - Repligen Corporation (NASDAQ:RGEN) today announced it will report financi... Continue Reading7/6/20127:00 AM ETPress ReleaseRepligen to Present at JMP Securities Healthcare Conference 20127/6/2012 SummaryRepligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate upda... Continue Reading6/25/201210:26 AM ETPress ReleaseRepligen Added to the Russell 2000 Index6/25/2012 SummaryRepligen Corporation (NASDAQ:RGEN) today announced that the Company’s stock has been added to the Russell 2000 ® index, a subset of the Ru... Continue Reading6/22/20127:00 AM ETPress ReleaseRepligen Receives Complete Response Letter from FDA for RG1068 NDA6/22/2012 SummaryRepligen Corporation (NASDAQ:RGEN) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration ... Continue Reading5/30/2012Press ReleaseRepligen to Present at Jefferies 2012 Global Healthcare Conference5/30/2012 Continue Reading5/7/2012Press ReleaseRepligen Announces Support of Amended Stockholder Proposal5/7/2012 Continue Reading5/3/2012Earnings ReleaseRepligen Reports First Quarter 2012 Financial Results5/3/2012 Continue Reading4/30/2012Press ReleaseRepligen Announces Conference Call to Report First Quarter of 2012 Financial Results4/30/2012 Continue Reading4/26/2012Press ReleaseRepligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting4/26/2012 Continue Reading4/25/2012Press ReleaseRepligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy4/25/2012 Continue Reading4/11/2012Press ReleaseMichael A. Griffith Appointed to Repligen Board of Directors4/11/2012 Continue Reading3/23/2012Press ReleaseRepligen Announces FDA Advisory Committee Date for SecreFlo™ NDA3/23/2012 Continue Reading3/16/2012Earnings ReleaseRepligen Reports Financial Results for the Quarter and Nine-Month Fiscal Year Ended December 31, 20113/16/2012 Continue Reading3/15/2012Press ReleaseRepligen Initiates Phase 1 Clinical Trial of RG2833 in Patients with Friedreich’s Ataxia3/15/2012 Continue Reading3/5/2012Press ReleaseRepligen Announces Submission of Marketing Authorization Application in EU for SecreFlo(TM) to Improve Pancreatic Imaging in Patients with Pancreatitis3/5/2012 Continue Reading2/29/2012Press ReleaseRepligen to Present at Cowen and Company Health Care Conference2/29/2012 Continue Reading2/21/2012Earnings ReleaseRepligen Reports Preliminary Financial Results for the Quarter and Nine-Month Fiscal Period Ended December 31, 20112/21/2012 Continue Reading2/21/2012Press ReleaseRepligen Announces FDA Grant of Priority Review for SecreFlo™ NDA2/21/2012 Continue Reading2/7/2012Press ReleaseRepligen to Present at BIO CEO & Investor Conference2/7/2012 Continue Reading2/7/2012Press ReleaseRepligen Launches New Products in OPUS™ Line of Pre-Packed Chromatography Columns2/7/2012 Continue Reading12/27/2011Earnings ReleaseRepligen Reports Second Quarter Fiscal Year 2012 Financial Results Achieves Record Bioprocessing Product Sales12/27/2011 Continue Reading12/21/2011Press ReleaseRepligen Announces Submission of New Drug Application for SecreFlo™ for Improved Pancreatic Imaging In Patients with Pancreatitis12/21/2011 Continue Reading12/20/2011Press ReleaseRepligen Completes Acquisition of Novozymes Biopharma Sweden AB12/20/2011 Continue Reading10/27/2011Press ReleaseRepligen Acquires Business of Novozymes Biopharma Sweden AB Creates World-Leading Supplier of Products for Manufacturing Biologic Drugs Accelerates Path to Near-Term, Sustainable Profitability10/27/2011 Continue Reading10/26/2011Press ReleaseRepligen Announces Conference Call of Second Quarter Fiscal Year 2012 Results10/26/2011 Continue Reading10/4/2011Press ReleaseRepligen Provides Q2 FY2012 Corporate Update Regulatory Progress on SecreFlo™ and Record Sales of Bioprocessing Products10/4/2011 Continue Reading8/31/2011Press ReleaseRepligen to Present at Upcoming Investor Conferences8/31/2011 Continue Reading8/11/2011Press ReleaseRepligen Announces Robert A. Spurr Joins Company as Senior Vice President of Sales and Marketing and Chief Commercial Officer8/11/2011 Continue Reading7/27/2011Earnings ReleaseRepligen Reports First Quarter Fiscal Year 2012 Financial Results7/27/2011 Continue Reading7/21/2011Press ReleaseRepligen Announces Initiation of RG1068 Pilot Study to Improve Identification and Characterization of Pancreatic Cancer7/21/2011 Continue Reading7/20/2011Press ReleaseRepligen Announces Conference Call of First Quarter Fiscal Year 2012 Results7/20/2011 Continue Reading7/15/2011Press ReleaseKaren A. Dawes Elected as Repligen Co-chairperson of the Board of Directors7/15/2011 Continue Reading6/23/2011Press ReleaseRepligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy6/23/2011 Continue Reading6/9/2011Earnings ReleaseRepligen Reports Fourth Quarter and Fiscal Year 2011 Financial Results and Updates Expectations and Corporate Goals for Fiscal Year 20126/9/2011 Continue Reading6/7/2011Press ReleaseRepligen Announces Conference Call to Discuss Fiscal Year 2011 Financial Results and Update Fiscal Year 2012 Financial Expectations and Corporate Strategy6/7/2011 Continue Reading6/1/2011Press ReleaseRepligen Concludes Pre-NDA Meeting with FDA for RG10686/1/2011 Continue Reading5/19/2011Press ReleaseRepligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy5/19/2011 Continue Reading4/21/2011Earnings ReleaseRepligen Reports Preliminary Fiscal Year 2011 Financial Results and Financial Guidance and Development Goals for Fiscal Year 20124/21/2011 Continue Reading4/15/2011Press ReleaseRepligen Announces Conference Call to Discuss Preliminary Fiscal Year 2011 Financial Results and Fiscal Year 2012 Corporate Goals and Financial Expectations4/15/2011 Continue Reading4/8/2011Press ReleaseRepligen to Present at the Biocentury and Thomson Reuters 18th Annual Future Leaders in the Biotech Industry Conference4/8/2011 Continue Reading3/14/2011Press ReleaseRepligen Reports Positive Phase 3 Clinical Trial Results for RG1068 in Pancreatic Imaging3/14/2011 Continue Reading3/14/2011Press ReleaseRepligen Announces Conference Call to Discuss Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging3/14/2011 Continue Reading3/7/2011Press ReleaseRepligen Reports Phase 2b Results for RG2417 for Bipolar Depression3/7/2011 Continue Reading3/1/2011Press ReleaseRepligen to Present at the Cowen and Company 31st Annual Healthcare Conference3/1/2011 Continue Reading2/9/2011Earnings ReleaseRepligen Reports Third Quarter Fiscal Year 2011 Financial Results2/9/2011 Continue Reading2/7/2011Press ReleaseRepligen to Present at the BIO CEO & Investor Conference2/7/2011 Continue Reading1/31/2011Press ReleaseRepligen Announces Conference Call of Third Quarter Fiscal Year 2011 Results1/31/2011 Continue Reading1/20/2011Press ReleaseRepligen Licenses Rights to Use of HDAC3 Inhibitors for Memory Disorders1/20/2011 Continue Reading12/15/2010Press ReleaseRepligen Receives $1.4 Million Research Grant from the Muscular Dystrophy Association to Support Spinal Muscular Atrophy Development Program12/15/2010 Continue Reading11/10/2010Press ReleaseRepligen to Present at the Lazard Capital Markets 7th Annual Healthcare Conference Wednesday, November 17th, 2:45 p.m. EST11/10/2010 Continue Reading11/2/2010Press ReleaseRepligen Reports Second Quarter Fiscal Year 2011 Financial Results11/2/2010 Continue Reading10/22/2010Press ReleaseRepligen Announces Conference Call of Second Quarter Fiscal Year 2011 Results Tuesday, November 2nd, 3:00 p.m. EDT10/22/2010 Continue Reading9/30/2010Press ReleaseRepligen Announces Completion of Patient Enrollment in Phase 2b Clinical Trial of RG2417 for Bipolar Depression9/30/2010 Continue Reading8/31/2010Press ReleaseRepligen to Present at the Rodman & Renshaw Annual Global Investment Conference Monday, September 13th, 12:05 p.m. EDT8/31/2010 Continue Reading8/5/2010Press ReleaseRepligen Reports First Quarter Fiscal Year 2011 Financial Results Product Sales Increase by 73%8/5/2010 Continue Reading8/2/2010Press ReleaseRepligen Receives Additional Research Grants to Support Development of HDAC Inhibitors for Friedreich’s Ataxia and Huntington’s Disease8/2/2010 Continue Reading7/26/2010Press ReleaseRepligen Announces Conference Call of First Quarter Fiscal Year 2011 Results Thursday, August 5th 10:00 a.m. EDT7/26/2010 Continue Reading6/9/2010Earnings ReleaseRepligen Reports Fourth Quarter and Fiscal Year 2010 Financial Results6/9/2010 Continue Reading6/2/2010Press ReleaseRepligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results Wednesday, June 9th 10:00 a.m. EDT6/2/2010 Continue Reading5/27/2010Press ReleaseRepligen Announces FDA and EMA Approval of Re-analysis of Images from Phase 3 Trial of RG1068 for Pancreatic Imaging5/27/2010 Continue Reading5/24/2010Press ReleaseRepligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreich’s Ataxia5/24/2010 Continue Reading5/13/2010Press ReleaseRepligen Files Investigational New Drug Application with FDA for First Drug Targeting the Core Genetic Defect of Friedreich’s Ataxia5/13/2010 Continue Reading4/30/2010Press ReleaseRepligen Reports Notice of Allowance of United States Patent Covering the Use of Uridine to Treat the Symptoms of Bipolar Disorder4/30/2010 Continue Reading4/16/2010Earnings ReleaseRepligen Reports Preliminary Fiscal Year 2010 Financial Results and Provides Financial Guidance and Development Goals for Fiscal Year 20114/16/2010 Continue Reading3/3/2010Press ReleaseRepligen Announces Acquisition of Chromatography Technology Platform "Plug and Play" Products Create Broad Opportunity in Biopharmaceutical Manufacturing3/3/2010 Continue Reading2/4/2010Earnings ReleaseRepligen Reports Third Quarter Fiscal Year 2010 Financial Results2/4/2010 Continue Reading2/3/2010Press ReleaseRepligen Receives Notice of Allowance for Recombinant Protein A Patent2/3/2010 Continue Reading2/1/2010Press ReleaseRepligen to Present at the BIO CEO & Investor Conference Monday, February 8th, 2:00 p.m. EST2/1/2010 Continue Reading1/29/2010Press ReleaseRepligen Announces Conference Call of Third Quarter Fiscal Year 2010 Results Thursday, February 4th, 10:00 a.m. EST1/29/2010 Continue Reading1/28/2010Press ReleaseRepligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A1/28/2010 Continue Reading12/15/2009Press ReleaseRepligen Receives Second Research Grant from the Muscular Dystrophy Association to Support Friedreich’s Ataxia Preclinical Development Program12/15/2009 Continue Reading12/9/2009Press ReleaseRepligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging12/9/2009 Continue Reading12/8/2009Press ReleaseRepligen Announces Conference Call to Discuss Phase 3 Clinical Results of RG1068 in MRI Imaging of the Pancreas Wednesday, December 9th, 8:30 a.m. EST12/8/2009 Continue Reading11/5/2009Press ReleaseRepligen Reports Second Quarter Fiscal Year 2010 Financial Results11/5/2009 Continue Reading11/3/2009Press ReleaseRepligen to Present at the Merriman Curhan Ford 6th Annual Investor Summit Tuesday, November 10th, 1:40 p.m. EST11/3/2009 Continue Reading10/29/2009Press ReleaseRepligen Announces Conference Call of Second Quarter Fiscal Year 2010 Results Thursday, November 5th, 10:00 a.m. EST10/29/2009 Continue Reading10/22/2009Press ReleaseRepligen Licenses Potential Treatment for Spinal Muscular Atrophy; Conference call scheduled for Friday, October 23rd, 8:30 a.m. EDT10/22/2009 Continue Reading10/19/2009Press ReleaseRepligen Announces Completion of Patient Treatment in Phase 3 Clinical Trial of RG1068 in MRI Imaging of the Pancreas10/19/2009 Continue Reading9/25/2009Press ReleaseRepligen Announces Identification of Drug Target for Friedreich's Ataxia; Study Published in the September 25, 2009 Issue of 'Chemistry & Biology'9/25/2009 Continue Reading9/2/2009Press ReleaseRepligen to Present at the Rodman & Renshaw 11th Annual Healthcare Conference Wednesday, September 9th, 2:25 p.m. EDT9/2/2009 Continue Reading8/25/2009Press ReleaseRepligen Elects Glenn L. Cooper, M.D. to the Board of Directors8/25/2009 Continue Reading8/6/2009Press ReleaseRepligen Reports First Quarter Fiscal Year 2010 Financial Results8/6/2009 Continue Reading7/30/2009Press ReleaseRepligen Announces Conference Call of First Quarter Fiscal Year 2010 Results Thursday, August 6th, 10:00 a.m. EDT7/30/2009 Continue Reading6/11/2009Press ReleaseRepligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results6/11/2009 Continue Reading6/4/2009Press ReleaseRepligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results Thursday, June 11th, 10:00 a.m. EDT6/4/2009 Continue Reading3/31/2009Press ReleaseRepligen Licenses Patent Rights for Treatment of Bipolar Disorder3/31/2009 Continue Reading3/9/2009Press ReleaseRepligen to Present at the Cowen & Company 29th Annual Healthcare Conference, Monday, March 16th, 2:25 p.m. EDT3/9/2009 Continue Reading2/12/2009Press ReleaseRepligen Announces ISO 9001:2000 Certification2/12/2009 Continue Reading2/5/2009Press ReleaseRepligen Reports Third Quarter Fiscal Year 2009 Financial Results2/5/2009 Continue Reading2/2/2009Press ReleaseRepligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST2/2/2009 Continue Reading1/29/2009Press ReleaseRepligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results Thursday, February 5th, 10:00 a.m. EST1/29/2009 Continue Reading11/6/20084:00 PM ETPress ReleaseRepligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder11/6/2008 Continue Reading11/6/20084:00 PM ETEarnings ReleaseRepligen Reports Second Quarter Fiscal Year 2009 Financial Results11/6/2008 Continue Reading11/3/20084:00 PM ETPress ReleaseRepligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference11/3/2008 Continue Reading10/30/20084:00 PM ETPress ReleaseRepligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results10/30/2008 Continue Reading9/17/20084:00 PM ETPress ReleaseRepligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT9/17/2008 Continue Reading9/16/20084:00 PM ETPress ReleaseRepligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington’s Disease Model9/16/2008 Continue Reading9/4/20084:00 PM ETPress ReleaseRepligen Receives Research Grants to Support Friedreich’s Ataxia Development Program9/4/2008 Continue Reading8/7/20084:00 PM ETEarnings ReleaseRepligen Reports First Quarter Fiscal Year 2009 Financial Results8/7/2008 Continue Reading7/31/20084:00 PM ETPress ReleaseRepligen Announces Conference Call of First Quarter Fiscal Year 2009 Results7/31/2008 Continue Reading7/1/20084:00 PM ETPress ReleaseRepligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors7/1/2008 Continue Reading6/30/20084:00 PM ETPress ReleaseRepligen Added to Russell 3000 Index6/30/2008 Continue Reading6/18/20084:00 PM ETPress ReleaseRepligen Announces Share Repurchase Program6/18/2008 Continue Reading6/12/20084:00 PM ETPress ReleaseRepligen Announces Plans to Initiate a Phase 2b Trial for RG2417 in Bipolar Disorder6/12/2008 Continue Reading6/12/20084:00 PM ETEarnings ReleaseRepligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results6/12/2008 Continue Reading6/6/20084:00 PM ETPress ReleaseRepligen Announces Conference Call of Fourth Quarter and Fiscal Year 2008 Results6/6/2008 Continue Reading4/16/20084:00 PM ETPress ReleaseRepligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging4/16/2008 Continue Reading4/8/20084:00 PM ETPress ReleaseRepligen Announces Settlement with Bristol-Myers Squibb in Orencia® Lawsuit4/8/2008 Continue Reading4/7/20084:00 PM ETPress ReleaseRepligen Announces Conference Call to Update Orencia® Lawsuit Tuesday, April 8th, 9:00 a.m. EST4/7/2008 Continue Reading3/26/20084:00 PM ETPress ReleaseRepligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging3/26/2008 Continue Reading2/7/20084:00 PM ETEarnings ReleaseRepligen Reports Third Quarter Fiscal Year 2008 Financial Results2/7/2008 Continue Reading Displaying 1 to 9 (of 324 releases) « 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 » View Source
Repligen Corporation's product roadmap and expansion strategy for 2024 through to 2026 focuses on maintaining its leadership in bioprocessing technologies while driving growth through innovation and strategic acquisitions. The company plans to continue enhancing its core areas of Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins, leveraging its global manufacturing footprint, which includes key sites in the U.S., Estonia, France, Germany, Ireland, the Netherlands, and Sweden 171819. With the recent CEO transition, Olivier Loeillot, who has extensive industry experience, will lead the company into its next phase of growth, focusing on commercial and corporate key accounts strategy, strategic planning, and evaluating potential business development opportunities 20.
17: About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company see our website at www.repligen.com, and follow us on LinkedIn. View Source18: Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. View Source19: About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, and the majority of our manufacturing sites are in the U.S., with additional key sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the our company see our website at www.repligen.com, and follow us on LinkedIn. View Source20: Mr. Loeillot currently oversees the Company’s four business units and the global commercial organization. His focus since joining Repligen has been on driving the commercial and corporate key accounts strategy, participating in strategic planning and evaluating potential business development opportunities. A nearly 30-year industry veteran, Mr. Loeillot previously served for a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the multi-billion dollar bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise solutions. Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing. View Source